(Q37715782)

22 August 2017

1 reference

title

Management of patients with myelodysplastic syndromes (English)

1 reference

22 August 2017

P Noël

1

1 reference

PubMed ID

2030615

22 August 2017

language of work or name

English

0 references

publication date

1 May 1991

1 reference

22 August 2017

1 reference

22 August 2017

66

1 reference

22 August 2017

5

1 reference

22 August 2017

485-497

1 reference

Proposals for the classification of the myelodysplastic syndromes

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Myelodysplastic syndromes: a scoring system with prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Myelodysplastic syndromes: a study of 101 cases according to the FAB classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Clinical-cytogenetic correlations in myelodysplasia (preleukemia)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Transfusional iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

The management of iron chelation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Mechanisms of glucocorticosteroid activity in patients with the preleukemic syndrome (hemopoietic dysplasia)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Danazol therapy in myelodysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Therapeutic efficacy of danazol in myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Danazol therapy in acquired idiopathic sideroblastic anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Effect of isotretinoin on survival of patients with myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

1-B-D arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Effects of calcitriol administration on calcium metabolism healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Circulating erythropoietin in patients with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Differential effect of recombinant human leukocyte interferon on human leukemic and normal myeloid progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Differentiation of myeloid leukaemic cells: new possibilities for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Therapy of secondary acute nonlymphocytic leukemia with cytarabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Bone marrow transplantation for myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

Partially matched bone marrow transplantation in patients with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962389-1

10.1016/S0025-6196(12)62389-1

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

2030615